Provided by Tiger Trade Technology Pte. Ltd.

Beam Therapeutics, Inc.

34.81
+0.88002.59%
Post-market: 35.230.4200+1.21%18:17 EDT
Volume:4.78M
Turnover:167.02M
Market Cap:3.58B
PE:-54.20
High:35.95
Open:33.64
Low:33.30
Close:33.93
52wk High:36.88
52wk Low:15.60
Shares:102.75M
Float Shares:89.94M
Volume Ratio:1.60
T/O Rate:5.32%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6423
EPS(LYR):-0.8100
ROE:-5.77%
ROA:-15.76%
PB:3.07
PE(LYR):-42.98

Loading ...

Beam Therapeutics (BEAM) Could Be 78% Undervalued As FDA Clears BEAM 304

Simply Wall St.
·
Jun 25

Why Beam Therapeutics (BEAM) Is Up 16.1% After FDA Clears Platform-Based PKU Gene-Editing Trial

Simply Wall St.
·
Jun 20

Beam Therapeutics says FDA clears IND for PKU candidate BEAM-304

Reuters
·
Jun 18

Beam Therapeutics Announces Clearance of Investigational New Drug Application for Beam-304 for the Treatment of Phenylketonuria (Pku) by the United States (U.S.) Food and Drug Administration

THOMSON REUTERS
·
Jun 18

Beam Stockholders Back Board, Leadership at Annual Meeting

TIPRANKS
·
Jun 09

Beam Therapeutics shareholders elect Class III directors at annual meeting

Reuters
·
Jun 09

Beam Therapeutics (BEAM) Gets a Buy from Canaccord Genuity

TIPRANKS
·
May 21

Beam Therapeutics presents Phase 1/2 data for BEAM-302

TIPRANKS
·
May 19

Beam Therapeutics presents Phase 1/2 BEAM-302 AATD trial data at ATS 2026

Reuters
·
May 19

Analysts Conflicted on These Healthcare Names: Omnicell (OMCL), Beam Therapeutics (BEAM) and Zentalis Pharmaceuticals (ZNTL)

TIPRANKS
·
May 13

Beam Therapeutics to present updated BEACON trial biomarker data for risto-cel in SCD at EHA2026

Reuters
·
May 12

Will Beam Therapeutics' (BEAM) Revenue Surge, Pipeline Updates and Added Liquidity Change Its Narrative?

Simply Wall St.
·
May 11

Evercore ISI Sticks to Their Buy Rating for Beam Therapeutics (BEAM)

TIPRANKS
·
May 09

Beam Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
May 07

Beam Therapeutics Q1 net loss narrows beating analyst estimates

Reuters
·
May 07

Beam Q1 FY26 net loss narrows 12.94% to $94.3 million

Reuters
·
May 07

Beam Therapeutics Q1 Operating Expenses USD 138.953 Million

THOMSON REUTERS
·
May 07

Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates

GlobeNewswire
·
May 07

A Look At Beam Therapeutics (BEAM) Valuation After TIME Recognition And BEACON Trial Progress

Simply Wall St.
·
May 03

Beam Therapeutics announces annual shareholder meeting via webcast

Reuters
·
Apr 18